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Background. For unknown reasons, the prevalence of thyroid autoimmune disorders is higher in patients with Down’s syndrome
than in the general population. The present case strongly supports a recent evaluation of propagating screening for thyroid
disease in this group of patients to assure early diagnosis of hypothyroidism. Methods. In a 25-year-old man diagnosed with
Down’s syndrome, clinical manifestations of hypothyroidism were lacking, but profound biochemical abnormalities were found
with particularly high levels of thyroid stimulating hormone (TSH). Antigenic properties of TSH were characterized using a
panel of anti-TSH antibodies. Results. Technical problems not infrequently associated with TSH measurements are convincingly
ruled out. Antigenic characterization of the patient’s circulating TSH revealed circulating forms of TSH diﬀerent from pituitary
TSH which closely resembled TSH recombinant human hormone. Conclusions. It appears counterintuitive that the bioactivity of
TSH decreases in the hypothyroid state as higher bioactivity of TSH is anticipated in hypothyroidism promoted by an increased
hypothalamic TRH drive. In contrast, diminished negative thyroid hormone feedback will enhance posttranslational glycosylation
of TSH subunits and increase sialylation of the carbohydrate side chains. Both exert a negative eﬀect on TSH bioactivity, only
compensated by the very high levels of the hormone as in the present case.
1.Introduction
For currently unknown reasons, the prevalence of thyroid
autoimmune disorders (AITD) is higher in patients with
Down’s syndrome than in the general population which is
observed in up to 3% of children. Most frequently, this
is associated with subclinical hypothyroidism. Systematic
screening for thyroid disease has been recently advocated
in this group of patients [1] to insure early diagnosis of
hypothyroidism.
2. Patient andMethods
2.1. Patient. In a 25-year-old man with Down’s syndrome
diagnosed at one month of life because of delayed growth,
a thyroid biochemical workup (thyrotropin, TSH; free2 Journal of Thyroid Research
thyroxin, FT4 and free triiodothyronine, FT3) was per-
formed on the request of his psychiatrist. The patient had
no apparent clinical evidence of a thyroid disorder and
was never tested before for a thyroid disorder although
he had a positive family history including spontaneous
hypothyroidism in his grandmother and Graves’ disease in
his mother. The young man was not on medication at the
time of blood sampling; his weight was 56kg and his pulse
60/min.
The following thyroid test results were obtained: TSH:
1392mIU/L (reference value: 0.25–4.0mIU/L), FT4:
0.66pmol/L (reference value: 8.2–18pmol/L), and FT3:
1.14pmol/L (reference value: 4.2–8.3pmol/L) (Table 1).
Antithyroid peroxidase, antithyroglobulin, and anti-TSH
receptor antibodies (TRab) were determined, as well as the
biological activity of the latter. Additional assays included
total cholesterol, total testosterone, luteinizing hormone
(LH), follicle-stimulating hormone (FSH), prolactin, and
α-subunit. Results are summarized in Table 1.T R A b sw e r e
assayed at the time when TSH was 1200–1540mIU/L. The
result of the TRAK assay was 216U/L. The assay of the
biological activity of TRAb indicated that both stimulating
and blocking activities were detectable. Stimulating activity
was 243% of control, and blocking amounted to 81%, a very
high value.
Because of the discrepancy between the clinical and
biological status and the unusual elevation of the TSH level,
a second blood sample was tested for TSH, FT4, and FT3
with qualitatively comparable results. In order to exclude
a potential interference from heterophilic antibodies, the
serum was pretreated with Heterophilic Binding Tubes
(HBT, Scantibodies, Villebon-Sur-Yvette, France). Unaltered
TSH, FT4, and FT3 levels argued against any interference.
We further excluded antithyroid hormone (anti-T3, anti-T4)
and anti-TSH autoantibodies (Table 1). Radioelectrophore-
sis showed no abnormality in binding of thyroxin to plasma
proteins.
Subsequently, the patient was treated with 50μgl e v o t h y -
roxine (Levothyrox) per day. He complained of fatigue and
a weight loss of 2kg after 15 days of treatment with an
unchanged pulse rate of 56bpm. Nuclear Magnetic Reso-
nance imaging of the adenohypophysis excluded a pituitary
adenoma with a rather small gland. Three months later, the
patient had no clinical complaints; his heart rate was stable
at 60 bpm. Levothyrox dose was increased to 100μg/d. TSH
l e v e lh a dd r o p p e dt o1 0 . 8 m I U / L ,a n dF T 4a sw e l la sF T 3
increased to 8.12pmol/L and 3.9pmol/L, respectively. Total
cholesterol was 4.8mol/L, alpha-subunit and prolactin levels
were within the reference range. To rule out any interference
of the very high initial concentrations of endogenous TSH
on the radioreceptor as well as of the biological assays, TRAb
levels were retested under levothyroxine treatment. With
an endogenous TSH concentration of 10,8mUI/L, TRAK
levels were 384U/L; the stimulating activity was 189%; and
the blocking activity was 77%, both not diﬀerent from the
previously obtained results.
2.2. Assay Methods. TSH assay was performed using three
immunoradiometric kits (Cis Bio International, IBA, Gif-
sur Yvette, France; Roche Diagnostic, Meylan, France and
Beckman-Coulter-Immunotech, Marseille, France). FT4 and
FT3 were measured using the Cis Bio International, IBA, and
Beckman-Coulter-Immunotech radioimmunoassays (RIA);
antithyroid peroxidase, antithyroglobulin, and anti-TSHR
antibodies were measured with the corresponding RIA
kit (Brahms-Diagnostica, Berlin, Germany); prolactin, LH,
FSH; and α-subunit were measured with the RIA kits from
Beckman-Coulter-Immunotech; testosterone was measured
with the Cis Bio International RIA. Total cholesterol was
measured using an enzymatic method (Olympus, France).
Anti-T4, anti-T3, and anti-TSH antibodies were assessed
with in-house RIA. The stimulating and blocking bio-
logical activities of anti-TSH antibodies were assayed as
described previously by Madec et al. [2, 3], and cAMP
was determined by RIA (Beckman-Coulter-Immunotech).
Radioelectrophoresis was performed according to an in-
house technique: serum incubated with 125It h y r o x i n
(7.4kBq/μL) was analyzed by agarose gel electrophoresis
with bromophenol blue staining of proteins. The relative
distribution of radioactive T4 among thyroxin binding
protein (TBG), albumin, transthyretin, and T4-binding
immunoglobulin when present is calculated as a function
of the total radioactivity added to the serum. Reference
values were established on 40 sera from euthyroid normal
subjects.
3. Immunochemical Characterizationof TSH
Earlier studies have shown that primary hypothyroidism
resulted in a drastic alteration of TSH epitope expression
[4], and that changes in TSH immunoreactivity could be
detected with anti-TSH antibodies. Indeed, both sialylation
and fucosylation could increase antibody recognition [4].
Therefore, the carbohydrate structure of the patient’s TSH
was studied and compared to that of recombinant TSH in
accordance to previous work [5]. As shown in Figure 1(a),
we ﬁrst performed comparative epitope mapping of recom-
binant TSH (recTSH) to the hormone circulating in can-
cer patients injected with Thyrogen (pool of 4 patients,
TSH = 311mIU/L). A panel of 10 monoclonal antibodies
targeting 3 main antigenic clusters was used in the best 15
distinct formats reported earlier [4]. Figure 1(a) shows that
recTSH and the circulating drug behaved quite similarly,
indicating that antibodies recognized the same forms in
both samples with equal eﬃciency. When the circulating
TSH of our patient and of thyroid cancer patients were
compared, immunoreactivities of both endogenous TSH
and Thyrogen (Figure 1(b)) were plotted on the same line
with a slope of 1.0511 in all formats, with r2 close to 1.
We also compared the immunoreactivities of the patient’s
circulating TSH to that of a pool of patients with overt
hypothyroidism (average TSH level: 177mIU/L) with unde-
tectable thyroid hormones and no thyroid autoantibodies.
Figure 1(c) shows that the two blood samples were similar
with a slope value of 0.968 and r2 value close to 1.
Therefore, the TSH of the patient clearly appeared to have
similar glycoepitopes as that from patients with primary
hypothyroidism.Journal of Thyroid Research 3
Table 1: Control of initial thyroid parameters TSH, FT3, and FT4 by diﬀerent assays and additional biological parameters.
Patient’s results Reference values
TSH
13921 0.25–4mIU/L
12002 0.27–4.2mIU/L
15403∗ 0.29–3.8mIU/L
FT4
0.664 8.2–18pmol/L
1.65 11.5–23pmol/L
1.35∗ 13–22.6pmol/L
FT3
1.144 4.2–8.3pmol/L
1.75 2.5–5.8pmol/L
1.95∗ 2.8–5.3pmol/L
Anti-thyroid peroxidase antibodies (AbTPO)6 4047 <60kU/L
Thyroglobulin (Tg)1 < 0.7 <50μg/L
Anti-thyroglobulin antibodies (AbTg)6 198 <60kU/L
Anti-TSH receptor antibodies (TSHR)6 216 <1.0U/L
Blocking anti-TSHR7 81 <10%
Stimulating anti-TSHR7 243 100%
Anti-T3 antibodies7 4.9 <7.9%
Anti-T4 antibodies7 3.7 <7%
Anti-TSH antibodies7 13 <18%
Total cholesterol8 9.3 4.5–6.0mmol/L
Total Testosterone1 11.3 8.2–34.6nmol/L
Alpha-subunits3 2.8 <0.8IU/L
Prolactin3 1009 30–545mIU/L
Luteinizing hormone (LH)3 4.6 1.8–8.4IU/L
Follicle-stimulating hormone (FSH)3 18.3 2.2–10IU/L
Radioelectrophoresis:
(i) Thyroxin-Binding Protein 69.7 63.6–81.2%
(ii) Albumin 6.0 2.9–9.7%
(iii) Transthyretin 23.8 12.5–29.7%
(iv) Immunoglobulins 0.5 <2.0%
1CisBio, 2Modular Roche Diagnostic, 3IRMA Beckman Coulter, 4RIA lisophase Cis Bio, 5RIA Beckman Coulter, 6Brahms, 7in-house assay, Biological Center
Lyon Sud, 8Olympus. ∗Pretreatment with “Heterophilic Blocking Tube” scantibodies.
However,frompreviousstudiesusingidenticalimmuno-
typing we know that pituitary TSH and serum TSH from
patients with primary hypothyroidism deviate with a slope
value (standard deviation) of 2.124 (0.001), with r2 =
0.817 [6]. This ﬁnding supports the notion that TSH of
our patient was deﬁnitely abnormal as antibodies were able
to bind to these hormonal glycoforms in the same way as
to recombinant TSH and much more eﬃciently than to
pituitary normal TSH.
In summary, these data indicate that the high circulating
TSH levels in our patient were associated with profound
changes in hormone immunoreactivity, suggesting alter-
ations in the glycosylation pattern similar to those found
in overt primary hypothyroidism. Using TSH preparations
modiﬁed for sialylation and/or fucosylation, we were able
to ascribe these structural changes to alterations in ter-
minal and/or internal glycosylation occurring in primary
hypothyroidism [4]. These modiﬁcations, independently or
in combination, alter the expression of most of the TSH
epitopes, presumably through a change in the β-subunit
conformation.
4. Discussion
The prevalence of overt thyroid diseases in children with
Down’ssyndromeisabout3%[7].However,thefrequencyof
serum TSH > 10mIU/L in the same population varies from
13 to 50%.
In most of the cases, the elevation of TSH is due to an
autoimmune dysfunction with the presence of anti-thyroid
antibodies. However, autoimmune subclinical hypothy-
roidism must be distinguished from defects in the biological
activity of the TSH molecule. TSH bioactivity in the plasma
of Down’s syndrome children is normal indicating that
subclinical hypothyroidism in these patients results from
primary thyroid dysfunction [8].4 Journal of Thyroid Research
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Figure 1: (a) Hormone circulating in cancer patients injected with
Thyrogen:poolof4patients,TSH=311mIU/L(Thyrogenpatients)
versusrecTSH.(b)Thyrogenpatientsversusyoungpatient.(c)Pool
of patients with overt hypothyroidism (TSH approx. 177mIU/L)
versus young patient.
In the present case, the unusually high elevation of the
serum TSH concentration and its combination with the
presence of a high level of TRAb, particularly of the blocking
type, raise several questions pertaining to (i) the duration
and the intensity of the primary thyroid insuﬃciency,
(ii) the role of the blocking TRAb in the mechanism of
hypothyroidism, and (iii) the possibility of changes in the
metabolic clearance and possibly in the immune-recognition
of the circulating TSH due to alterations in the glycosylation
pattern of the molecule.
Very high levels of TSH are usually observed in long-
lasting and severe hypothyroidism. In this case, however,
clinical manifestations, if any, were very mild, although
some improvement was noticed on thyroxine substitution.
Such discrepancy between clinical and biological status,
although unexplained, is not uncommon. The lack of
pituitary hypertrophy is more surprising if a case of long-
standing juvenile hypothyroidism is assumed. This supports
the alternative hypothesis that hypothyroidism, although
severe, was of recent onset, possibly related to the presence
of blocking TRAb.
Pituitary TSH is synthesized and secreted as a variable
mixture of a dozen of diﬀerent glycoforms. This polymor-
phisminﬂuencesthemetabolicclearancerateandbioactivity
of TSH. Indeed, sialylation of the hormone molecule pro-
longs its blood half-life by preventing its liver uptake. On the
other hand, several studies have shown that the bioactivity of
TSH is enhanced or reduced depending on the pathophysio-
logical conditions [9–11]. TSH, about 30kDa, belongs to the
glycoprotein hormone family. These glycoproteins share a
high degree of glycosylation and are heterodimers consisting
of a common α-subunit and a unique β-subunit, which
confers the biological and immunological speciﬁcity to each
hormone. TSH contains 3 N-glycan chains of complex type
constituting between 15 to 25% of its molecular mass.
The terminal glycosylation, the inner fucosylation, and
the degree of connection are three parameters of hetero-
geneity responsible for the natural polymorphism of this
hormone.
This paper shows that TSH expresses three of its main
epitopes to a diﬀerent extent according to the nature of
its glycosylation. The antibodies, which readily recognize
the glycoforms in the pituitary calibrator, are also able to
recognize the same glycoforms present in serum TSH (or
the recombinant hormone), but present in small quantity
because of the metabolic clearance. This is the basis of
the currently marketed measurement systems since all
assays are calibrated against the 2nd International Reference
Preparation (IRP) of human pituitary TSH, 80/558. Since
these forms are decreasing in the circulation and the more
sialylated forms of TSH increase as the hypothyroidism
develops, it can be assumed that monoclonal antibodies bind
less tonormallyexpectedand more todiseased formsof TSH
for which they display increased eﬃciency. This diﬀerential
recognition may in turn aﬀect TSH measurement, leading to
a biased follow up of the hormone level, especially under T4
treatment when TSH levels could be normalized. Despite the
limitations, we were able to show that TSH of this patient is
structurally abnormal and virtually identical to hypothyroidJournal of Thyroid Research 5
TSH, reﬂecting probably a long-lived TSH with very low
biological activity.
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